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Coagulopathy in Critically Ill
Abbreviations: aPTT ϭ activated partial thromboplastin time; DIC ϭ disseminated intravascular coagulation; HELLP ϭ hemolysis, elevated liver enzymes, and low platelets; HIT ϭ heparin-induced thrombocytopenia; HUS ϭ hemolytic uremic syndrome; PF4 ϭ platelet factor 4; PT ϭ prothrombin time; TTP ϭ thrombotic thrombocytopenic purpura; vWD ϭ von Willebrand disease; vWF ϭ von Willebrand factor E ven though coronary, cerebrovascular, and venous thromboses are the leading killers of adults in ICUs, clinicians often have greater apprehension about bleeding than clotting. These concerns may stem from a sense of responsibility for bleeding following procedures or anticoagulant therapy, or perhaps it is the mere fact that hemorrhage is often visible externally, whereas thrombosis is more clandestine. Fortunately, humans are largely protected from clinically significant bleeding by the following three hemostatic systems: intact vasculature; platelets; and soluble clotting factors. Significant bleeding is rare until two of the three systems malfunction, and then the magnitude of each failure often must be significant. This article, the initial one in a two-part series on coagulation disorders in the ICU, focuses on the causes and treatment of the most common coagulation disorder in critically ill patients, namely thrombocytopenia, and it also briefly discusses disorders of platelet function despite normal platelet counts.
Platelet Disorders
Platelets form the first line of defense when endothelial surfaces are breached. Exposure of the subendothelial layer of vessels results in exposure of tissue factor, collagen, and von Willebrand factor (vWF), which promote fibrinogen and vWF-mediated platelet aggregation. In rapid succession, platelets change shape, degranulate, and expose surface phospholipids that generate small amounts of thrombin, triggering clotting amplification. Hence, the deficiency or dysfunction of platelets represents a serious hemostatic problem.
Thrombocytopenia
Thrombocytopenia is the most common coagulation problem in the ICU with an incidence of 15 to 60% depending on the definition used, population evaluated, and period of ICU stay studied. [1] [2] [3] [4] [5] [6] [7] [8] About half of all ICU patients with thrombocytopenia present with the condition 6, 9 ; the remainder acquire it promptly. 9 The highest incidence is seen in patients with severe sepsis. 1,9 -12 Surgical and trauma patients reportedly have a higher frequency than medical patients. 7, 8 Patients receiving dialysis support also frequently exhibit thrombocytopenia. 6 Definition and Implications: Traditionally, thrombocytopenia has been defined as a platelet count of Ͻ 150 ϫ 10 9 /L, but in critically ill patients a threshold of Ͻ 100 ϫ 10 9 /L has been suggested, 13, 14 due to the relatively high incidence and lack of significant bleeding with counts between 100 and 150 ϫ 10 9 /L. A category of severe thrombocytopenia (Ͻ 50 ϫ 10 9 /L) has also been designated but fortunately is uncommon, occurring in just 2 to 15% of ICU patients. [1] [2] [3] [4] [5] [6] 8, 13 Thrombocytopenia is important because it increases the risk of bleeding, alters plans for care, and serves as a marker of morbidity and mortality. Thrombocytopenia may also be a manifestation of a disease that promotes clotting, such as heparininduced thrombocytopenia (HIT) or disseminated intravascular coagulation (DIC). The threshold at which bleeding risk increases significantly is debated but probably lies below, maybe even well below, 100 ϫ 10 9 /L. In the ICU, counts Ͻ 100 ϫ 10 9 /L have been associated with a 10-fold increased risk of bleeding compared to those between 100 and 150 ϫ 10 9 /L. 1 Lower platelet counts are associated with an even higher risk of hemorrhage, especially counts below 50 ϫ 10 9 /L, 1,2,13 and although rare, spontaneous intracerebral hemorrhage is usually a complication only when platelet counts fall below 10 ϫ 10 9 /L. 15 Tradition largely drives practice with regard to care of the thrombocytopenic patient. Invasive procedures are commonly avoided when the counts are below 50 ϫ 10 9 /L and sometimes even when 50 to 100 ϫ 10 9 /L, especially if the procedure involves the neuraxis or other critical or difficult-to-access sites. 16 -18 For patients with intact soluble clotting factors not undergoing invasive procedures, this practice may be overly conservative. Surgical bleeding is uncommon with platelet counts Ͼ 50 ϫ 10 9 /L, 19, 20 and oncology data indicate that the risk of spontaneous bleeding does not increase until counts fall below 20 ϫ 10 9 /L and perhaps even 10 ϫ 10 9 /L. [21] [22] [23] In patients with aplastic anemia, this threshold may even be as low as 5 ϫ 10 9 /L. 23 Surprisingly, even among patients with severe sepsis receiving the anticoagulant activated protein C, significantly higher bleeding rates are not seen until platelet counts decline below 30 ϫ 10 9 /L unless invasive procedures are performed. 24, 25 Even though concern for bleeding in thrombocytopenic patients is understandable, oftentimes such patients are unnecessarily exposed to risks of platelet transfusions. 26 Ironically, platelet transfusions decrease endogenous platelet production because the c-Mpl receptor on the surface of transfused platelets binds and inactivates thrombopoietin produced by the liver. 27 Furthermore, platelet transfusions place the patient at risk for other complications. 17, 18 Platelets are obtained from blood donors, and, as such, they carry a risk, although very small, of transmitting infections such as HIV or hepatitis viruses. In addition, transfusion-related acute lung injury can also occur after platelet transfusions. Finally, platelets increase the propensity to clot, which is why they are given to bleeding patients or those at risk for bleeding. However, platelet transfusions may actually cause excessive clotting or deep vein thromboses in some patients.
Although platelet transfusions are often used to increase the absolute platelet count in many critically ill patients, they may be unnecessary, ineffective, or contraindicated in certain patients. In addition to the complications just listed, platelet transfusions also can exacerbate clotting in many of the prothrombotic thrombocytopenic conditions, such as thrombotic thrombocytopenic purpura (TTP) and HIT. In fact, in DIC, where the thrombocytopenia is a result of excessive formation and degradation of clots, treatment of the underlying cause is indicated over platelet transfusion. Likewise, anticoagulation to prevent clots from forming, concurrently with discontinuation of the heparin, is also part of the treatment for HIT.
Independent of bleeding, studies have consistently demonstrated an association between thrombocytopenia and poor clinical outcomes. For example, low platelet counts have been associated with longer ICU and hospital lengths of stay 3, 6, 7, 28 and are an independent predictor of ICU mortality and lower rates of long-term survival. 1, 2, 6, 7, 12, 29 In fact, data suggest that the severity of thrombocytopenia is inversely related to survival in critically ill patients, and that sustained thrombocytopenia over 4 days is associated with a fourfold to sixfold increase in mortality. 1, 9 The relationship between thrombocytopenia and poor outcomes is particularly prominent for patients meeting the formal DIC criteria. 24, 30 Although the reasons for the association between thrombocytopenia and poor outcomes are speculative, they likely relate to the seriousness of conditions causing the thrombocytopenia (eg, severe sepsis and neoplasia).
Etiology
The cause of thrombocytopenia in most ICU patients is multifactorial, involving some combination of the following four mechanisms: increased destruction or consumption; decreased production; dilution; and sequestration (Table 1) . 31 Spurious Thrombocytopenia: The initial step in evaluating thrombocytopenia should always be to make sure the laboratory result really reflects a low platelet count. Spurious thrombocytopenia, or pseudothrombocytopenia, arises from platelets clumping in the collection tubes due to either ethylenediaminetetraacetic acid-dependent antibodies or insufficient anticoagulant. The reasons for the development of antibodies are in question. The process, however, seems to be most common among patients with severe sepsis, or autoimmune, neoplastic, or liver diseases. 32 As a result, automated counters fail to recognize clumped platelets as such due to their abnormally large size, resulting in a falsely decreased reported platelet count. If spurious thrombocytopenia is suspected because the laboratory finding does not fit the clinical picture or clumped platelets are seen on the peripheral smear, blood should be redrawn in heparin or citratecontaining collection tubes and assayed again for platelet count using the automated counter and/or examined microscopically. The examination of platelet size may also provide clues to the etiology of thrombocytopenia. Larger platelets are usually associated with diseases of increased platelet turnover and adequate marrow production (eg, idiopathic thrombocytopenic purpura), whereas small platelets are more likely to be associated with production disorders. 33 
Increased Platelet Destruction or Consumption
Increased platelet destruction is the most common mechanism for thrombocytopenia and may occur through immune-mediated and non-immune-mediated mechanisms. 34 Nonimmune causes include DIC as seen with some malignancies, severe sepsis, trauma, or obstetrical catastrophes, and physical destruction as seen with cardiopulmonary bypass or giant hemangiomas. 35, 36 The physical destruction is thought not to be mediated by specific antibodies, but some of the conditions may indeed occur via an unknown immune-mediated process. In addition, some of the thrombocytopenia in these conditions may simply reflect the consumption of platelets in the overexuberant formation of clots. . Although rare to develop in the ICU, patients may also present with other thrombotic microangiopathies, such as TTP-hemolytic uremic syndrome (HUS). In these cases, thrombocytopenia results from platelets aggregating with abnormally large vWF multimers that result from a deficiency in a vWF-cleaving protease. 37 The often profound thrombocytopenia is accompanied by elevated serum lactate dehydrogenase levels and the presence of schistocytes on the peripheral smear representing mechanical destruction of erythrocytes. 38 Only microangiopathic hemolytic anemia and thrombocytopenia are required for the diagnosis, despite the description of a "classic pentad" of TTP-HUS, which also includes renal dysfunction, neurologic abnormalities, and low-grade fever. 39 Numerous conditions, including cancer, pregnancy, autoimmune conditions such as antiphospholipid antibody syndrome, and pneumococcal infection can be associated with "TTP-like" syndromes. Likewise, medications, such as cyclosporine, clopidogrel, and some chemotherapeutic agents, can produce a similar syndrome. 14 The absence of an increased aPTT or PT in patients with TTP-HUS can sometimes help differentiate it from DIC, which also can have schistocytes on the peripheral smear. Unfortunately, increased coagulation parameters are not universally present in DIC, making the distinction difficult at times. Low fibrinogen levels and prolonged thrombin times are also commonly present in patients with DIC but rarely occur with TTP-HUS ( Table 2) . A temperature Ͼ 39°C (102°F) may also help to distinguish DIC from TTP-HUS because fever, when present in the latter condition, is almost always low grade. 40 Hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome of pregnancy represents another condition with hemolysis and thrombocytopenia that may be difficult to discriminate from TTP-HUS 14 ( Table 2 ). Elevated liver enzymes may be helpful in differentiating the two, but the pregnant state itself is less helpful because it is also a risk factor for TTP. However, HELLP primarily occurs during the third trimester, so thrombocytopenia prior to 20 weeks of gestation is almost never HELLP syndrome. Because HELLP syndrome usually resolves within 72 h of delivery, continued worsening of thrombocytopenia beyond this time should prompt the strong consideration of TTP.
DIC, TTP, and Hemolysis, Elevated Liver Enzymes, Low Platelets Syndrome: DIC is usually associated

Immune-Mediated Damage
Drug-Induced, Immune-Mediated Thrombocytopenia: Immune-mediated thrombocytopenia occurs via the production of platelet antibodies with subsequent destruction. The antibodies can be idiopathic or induced by drugs, [41] [42] [43] infections (eg, cytomegalovirus, HIV, Epstein-Barr virus, or parvovirus), or alloimmune disease following transfusion or transplantation. Many drugs have been implicated as causes of thrombocytopenia. Table 3 presents a partial list of nonchemotherapeutic agents (a more extensive list can be found at http://moon.ouhsc.edu/ jgeorge/DITP.html). In the ICU, drug-induced thrombocytopenia can be overlooked because its onset often occurs a week or more after beginning therapy with the medication, 42 there are no distinguishing clinical features, and numerous other possible etiologies for thrombocytopenia exist. Nonetheless, recognition is important because the problem may sometimes be reversed by simply discontinuing the offending agent. The drug-induced destruction of platelets usually occurs via the formation of antiplatelet antibodies, which bind normal platelets in the presence of the sensitizing drug. 42, 44 Only a few drugs, such as procainamide, induce autoantibodies that react with platelets even in the absence of the drug. 45 Although specific drug platelet-associated antibodies have been demonstrated for numerous compounds, in vitro testing is usually not helpful because it lacks sensitivity and specificity. 46 A third mechanism of drug-induced thrombocytopenia involves a direct interaction between drug and platelets, resulting in immune destruction. Tirofiban, for example, interacts with the glycoprotein IIb/IIIa receptor on platelets, changing their shape and thereby facilitating antibody recognition. 47 HIT: Heparin is thought to be the most common noncytotoxic drug associated with thrombocytopenia. Although it is fairly common for platelet counts to reversibly decline modestly in the first few days after starting therapy with heparin (sometimes called type 1 HIT), the term HIT describes a specific syndrome of antibody formation, low platelets, and thrombosis. 48, 49 Occasionally referred to as type 2 HIT, the incidence of this syndrome varies widely by population studied with the highest rates seen among patients given high doses of unfractionated heparin on multiple occasions. Although well known for its devastating thrombotic complications, type 2 HIT occurs in Ͻ 5% of patients treated with unfractionated heparin for up to 7 days. 48 Any exposure to any amount or form of heparin can cause, or exac- erbate, HIT, including flushes for IV or arterial lines, use in dialysis machines, or subcutaneous dosing for deep venous thrombosis prophylaxis. Low-molecularweight heparins can also incite HIT, although much less frequently, 50 and now there is even a case report 51 of HIT resulting from the factor Xa inhibitor fondaparinux.
In patients with no, or distant, previous heparin exposure, the fall in platelet counts can take 5 to 10 days. However, in patients with a history of recent exposure, the process can occur within hours. Platelet counts below 10 ϫ 10 9 /L and bleeding are both exceedingly rare in patients with HIT. 48 In fact, the biggest risk for patients with HIT is thrombosis, which is 30 times more likely than in the general population. 52 The clots that result from HIT do not have to be unusual; in fact, the most common presentation of HIT is deep venous thrombosis.
The pathophysiology of HIT is complex and has been well reviewed elsewhere. 48 Briefly, heparin binds platelet factor 4 (PF4) forming a heparin-PF4 immune complex. Antibodies then bind to this immune complex and destroy platelets. An enzymelinked immunosorbent assay is available for the detection of heparin-PF4 antibodies, and although highly sensitive, the assay has low specificity. Most patients with PF4-heparin antibodies do not have HIT. 53 Functional assays, which measure platelet degranulation in response to PF4-heparin complexes, have higher specificity but are not widely available. 53 Treatment recommendations, largely stemming from expert advice because randomized large-scale trials are lacking, consist of the discontinuation of all forms of heparin and the initiation of therapy with a direct thrombin inhibitor at least until improvement of the platelet count. Once the platelet count has demonstrated at least partial recovery (eg, Ͼ 100 ϫ 10 9 /L), warfarin therapy can be started and should be continued for at least 3 months. 48 Treatment with a direct thrombin inhibitor should be continued until therapeutic anticoagulation from the warfarin has been achieved. Controversy exists regarding the safety of reexposure of HIT victims to heparin, but it is safe to say that reexposure should not occur for several months, and then only after heparin-PF4 antibodies are undetectable.
Dilutional Thrombocytopenia
Dilutional thrombocytopenia and concurrent soluble clotting factor deficiencies occur following massive blood product administration through the following two mechanisms: simple loss; and consumption without adequate replacement. There are no absolute rules for the volume of transfusion required for this problem to emerge, but replacement of the entire blood volume within a day, or half within 3 to 4 h, is often sufficient to precipitate a dilutional coagulopathy. The occurrence of dilutional coagulopathy is so variable that a strategy advocating a fixed recipe of blood product replacement probably does not make sense. Although one might suspect mild thrombocytopenia would result from dilution, surprisingly in cases where Ն 20 units of blood products are transfused, platelet counts below 50 ϫ 10 9 /L are not uncommon. 2 Dilutional coagulopathy is also commonly compounded by hypothermia resulting from patient exposure and the infusion of large volumes of cool fluids, 54 by acidosis resulting from underperfusion and the transfusion of acidic fluids, and by the presence of DIC in some patients. The contribution of hypothermia to coagulopathy can be significant because hypothermia impairs platelet activation, adhesion, and aggregation, 55 as well as the enzymatic activity of soluble clotting factors. 54 Distributional Thrombocytopenia: Sequestration in patients with marked splenomegaly resulting from portal hypertension or splenomegaly from other causes can result in distributional thrombocytopenia. The mechanism for the thrombocytopenia is likely multifactorial, including "pooling in the spleen," decreased production, and immune platelet destruction (especially in idiopathic thrombocytopenic purpura). 56 Patients with cirrhosis-induced portal hypertension may also have decreased platelet production because of reduced levels of thrombopoietin, normally produced by the liver 57 or from the toxic effects of ethanol on the marrow. 58 
Decreased Platelet Production
Bone marrow suppression results in a reduction in all cell lines, but it often manifests as thrombocytopenia because of the relatively short lifespan of platelets, especially if consumption is increased. Because drugs are the main culprit causing bone marrow suppression (Table 3) , all medicines, including nonprescription drugs, should be thoroughly reviewed and potential offenders discontinued, if possible. Clinicians recognize chemotherapeutic or immunosuppressive agents as causing dose-dependent hematosuppression. However, nonchemotherapeutic agents, like the antibiotic linezolid, may also result in decreased platelet production. 59 therapy), metastases, and nutritional deficiencies (eg, vitamin B 12 , folic acid, or iron) can also result in bone marrow suppression. 13 
Disorders of Platelet Function
Disorders of platelet function occur when platelet numbers are normal but activity is impaired by medications; the platelet environment, as in renal failure; or intrinsic platelet defects. These disorders are not readily apparent via simple examination of the platelet count from the CBC. Clinically, patients with dysfunctional platelets characteristically demonstrate abnormal mucosal or cutaneous bleeding, manifested as epistaxis, gingival bleeding, cutaneous petechiae, superficial ecchymoses, or menorrhagia. 31 If platelet dysfunction is suspected, specialized platelet function studies, which test the ability of platelets to aggregate and form a clot, should be ordered. The simplest of these is bleeding time, where the interaction between platelets and the blood vessel wall is measured by the time needed to stop bleeding after a cut in the skin. Unfortunately, bleeding time is poorly reproducible, insensitive, and time consuming. Newer studies of platelet function have been developed that measure the ability of platelets to aggregate in response to the addition of an external stimulus. Many of these tests are performed only in specialized laboratories and are not available clinically. A complete discussion of platelet aggregation testing is beyond the scope of this review and has been detailed elsewhere. [62] [63] [64] Medications that cause platelet dysfunction include aspirin, which irreversibly inhibits platelet aggregation, and a host of cyclooxygenase inhibitors that reversibly inhibit platelet function. The glycoprotein IIb/IIIa inhibitors, abciximab, tirofiban, and eptifibatide alone, or in combination with aspirin, are commonly used to deter rethrombosis after percutaneous coronary interventions. 42 Although all of these agents significantly impair platelet function, the effects of abciximab persist until new platelets are produced. Clopidogrel, a functionally related compound, inhibits adenosine diphosphateinduced platelet aggregation, preventing activation of the IIb/IIIa mechanism. In bleeding patients exposed to these medications, discontinuation of the drug may not be sufficient to return platelet function to normal, and transfusion of platelets may be needed to restore hemostasis.
Although patients with end-stage renal disease may have mild thrombocytopenia, more often they have a number of normal, but dysfunctional, platelets. 65 The pathophysiology behind this "uremic coagulopathy" has yet to be fully elucidated but is likely multifactorial. 65 Some speculate that decreased circulating RBCs resulting from reduced erythropoietin production cause platelets to travel in a more midstream position within vessels, rendering them further away and less likely to react to endothelial damage. 66 In addition, uremic toxins result in dysfunctional vWF and vWF-factor VIII complex, and impaired platelet aggregation. The treatment of longterm dialysis patients who are bleeding may require a multifaceted approach, including short-term dialysis to remove uremic toxins, 66 IV desmopressin to release factor VIII from endothelial storage sites and minimize the effect of dysfunctional vWF, 67, 68 IV conjugated estrogens (in men and women) to promote coagulation, 69 and in some cases, the administration of cryoprecipitate to increase the proportion of functional factor VIII, vWF, and fibrinogen. 70 Obviously, if the patient is significantly thrombocytopenic, platelet transfusions are also indicated.
A triad of very rare intrinsic platelet disorders can also result in functional thrombocytopenia, as follows: Bernard-Soulier syndrome, in which the glycoprotein Ib portion of the receptor is absent; Glanzmann thrombasthenia, in which the entire glycoprotein IIb/IIIa receptor is absent; and HermanskyPudlak syndrome, which is a platelet storage pool disease. In contrast to these rare conditions, von Willebrand disease (vWD) is a relatively common disorder that pathophysiologically bridges platelet and soluble clotting factor disorders. Fortunately, clinically significant bleeding is rare in almost all types of vWD, and when bleeding occurs it is usually confined to mucosal surfaces. vWD has several major types, and multiple subtypes are classified according to the quantity or functionality of vWF or its binding to platelet glycoprotein Ib receptors. A complete discussion of vWD is beyond the scope of this review and has been done nicely by others. 71 Suffice it to say that clinicians entertaining a diagnosis of vWD in a patient with easy bruising, skin bleeding, and prolonged bleeding from mucosal surfaces should consult a specialist in coagulation.
Conclusion
Thrombocytopenia is commonly seen in critically ill patients. In addition, some patients, such as those with uremia or vWD, may have dysfunctional platelets despite normal counts. When mild, thrombocytopenia may not increase the bleeding risk substantially, but severe thrombocytopenia is associated with both increased bleeding risk and higher mortality. As the most common coagulopathy in the ICU, the etiology of low platelet counts is often multifactorial resulting from the underlying disease state, medications, or as a result of consumption of thrombi. Although thrombocytopenia often improves with treatment of the underlying illness, an in-depth understanding of the causes of thrombocytopenia and subsequent action may raise platelet counts and prevent unnecessary deferment of invasive procedures or exposure to platelet transfusion risks in critically ill patients.
